11 C-Loperamide is an avid substrate for P-glycoprotein (P-gp), but it is rapidly metabolized to 11 C-N-desmethyl-loperamide ( 11 C-dLop), which is also a substrate for P-gp and thereby contaminates the radioactive signal in the brain. Should further demethylation of 11 C-dLop occur, radiometabolites with low entry into the brain are generated. Therefore, we evaluated the ability of 11 C-dLop to quantify the function of P-gp at the blood-brain barrier in monkeys. Methods: Six monkeys underwent 12 PET scans of the brain, 5 at baseline and 7 after pharmacologic blockade of P-gp. A subset of monkeys also underwent PET scans with 15 O-water to measure cerebral blood flow. To determine whether P-gp blockade affected peripheral distribution of 11 C-dLop, we measured whole-body biodistribution in 4 monkeys at baseline and after P-gp blockade. Results: The concentration of 11 C-dLop in the brain was low under baseline conditions and increased 5-fold after P-gp blockade. This increase was primarily caused by an increased rate of entry into the brain rather than a decreased rate of removal from the brain. With P-gp blockade, uptake of radioactivity among brain regions correlated linearly with blood flow, suggesting a high single-pass extraction. After correction for cerebral blood flow, the uptake of 11 C-dLop was fairly uniform among brain regions, suggesting that the function of P-gp is fairly uniformly distributed in the brain. On whole-body imaging, P-gp blockade significantly affected distribution of radioactivity only to the brain and not to other visually identified source organs. The effective dose estimated for humans was approximately 9 mSv/ MBq. Conclusion: PET with 11 C-dLop can quantify P-gp function at the blood-brain barrier in monkeys. The single-pass extraction of 11 C-dLop is high and requires correction for blood flow to accurately measure the function of this efflux transporter. The low uptake at baseline and markedly increased uptake after P-gp blockade suggest that 11 C-dLop will be useful to measure a wide range of P-gp functions at the blood-brain barrier in humans. Themembrane-boundt ransporter P-glycoprotein (P-gp) acts as an efflux pump in several organs of the body (1). At the blood-brain barrier, P-gp and at least 3 other closely related transporters can block the entry of many drugs and toxins. These substrates have a wide variety of chemical structures but tend to be ampiphilic (i.e., have lipophilic components and a positive charge). The physiologic function of P-gp is thought to protect the brain from toxins in the blood. P-gp may also have pathophysiologic importance. For example, overexpression of P-gp may block the entry of anticonvulsant agents in the area of the epileptogenic focus (2). In addition, decreased P-gp function in Alzheimer disease (3) and Parkinson disease (4) may lead to the accumulation of amyloid or to the exposure of dopamine-containing neurons to exogenous toxins, respectively. 99m/94m Tc-sestamibi (5) and 11 C-verapamil (6) are substrates of P-gp, but each of these agents has limitations for use at the blood-brain barrier. An effective radiotracer for P-gp at the blood-brain barrier should have high entry in the absence of P-gp. The function of P-gp can then be measured by the extent to which it blocks entry of the substrate radiotracer. In this regard, Tc-radiolabeled sestamibi is a poor agent for the brain, because the high molecular weight (783 atomic mass units) and positive charge of the radiotracer diminish its entry even in the absence of P-gp. Although 11 C-verapamil easily enters the brain after inhibition of P-gp, this radiotracer is rapidly metabolized to lipophilic radioactive compounds that also enter the brain. The presence of multiple radiolabeled species in the brain confounds quantitative analysis of P-gp function (7).
Themembrane-boundt ransporter P-glycoprotein (P-gp) acts as an efflux pump in several organs of the body (1) . At the blood-brain barrier, P-gp and at least 3 other closely related transporters can block the entry of many drugs and toxins. These substrates have a wide variety of chemical structures but tend to be ampiphilic (i.e., have lipophilic components and a positive charge). The physiologic function of P-gp is thought to protect the brain from toxins in the blood. P-gp may also have pathophysiologic importance. For example, overexpression of P-gp may block the entry of anticonvulsant agents in the area of the epileptogenic focus (2) . In addition, decreased P-gp function in Alzheimer disease (3) and Parkinson disease (4) may lead to the accumulation of amyloid or to the exposure of dopamine-containing neurons to exogenous toxins, respectively. 99m/94m Tc-sestamibi (5) and 11 C-verapamil (6) are substrates of P-gp, but each of these agents has limitations for use at the blood-brain barrier. An effective radiotracer for P-gp at the blood-brain barrier should have high entry in the absence of P-gp. The function of P-gp can then be measured by the extent to which it blocks entry of the substrate radiotracer. In this regard, Tc-radiolabeled sestamibi is a poor agent for the brain, because the high molecular weight (783 atomic mass units) and positive charge of the radiotracer diminish its entry even in the absence of P-gp. Although 11 C-verapamil easily enters the brain after inhibition of P-gp, this radiotracer is rapidly metabolized to lipophilic radioactive compounds that also enter the brain. The presence of multiple radiolabeled species in the brain confounds quantitative analysis of P-gp function (7) .
In the search for an improved radiotracer to measure P-gp function, we evaluated the 11 C-labeled version of loperamide, a nonprescription medication used to treat diarrhea. Loperamide is an opiate agonist and acts on m-receptors in the gut to slow motility and thereby treat diarrhea. Despite high doses and high plasma concentrations in human subjects, loperamide lacks central nervous system effects, because P-gp efficiently blocks virtually all brain entry (8) . 11 C-loperamide is an avid substrate for P-gp at the blood-brain barrier. For example, brain uptake is increased several fold both in P-gp knock-out mice and in monkeys after pharmacologic blockade of P-gp (9) . Unfortunately, 11 C-loperamide is rapidly metabolized to 11 C-Ndesmethyl-loperamide ( 11 C-dLop), which is also an avid substrate for P-gp (10) . Thus, after injection of 11 Cloperamide, brain radioactivity measured with PET derives from 2 compounds-namely, the parent radiotracer and its N-desmethyl metabolite. We compared 11 C-loperamide and 11 C-dLop in regard to the percentage contamination of brain radioactivity in P-gp knock-out mice at 30 min after injection of the radiotracer. For 11 C-loperamide, only 50% of extracted brain radioactivity was the parent radiotracer (9) . In contrast, for 11 C-dLop, 90% of brain radioactivity was the parent radiotracer (10) . Thus, compared with 11 C-loperamide, 11 C-dLop provides a PET signal from the brain of greater radiochemical purity, which allows the plasma concentrations of 11 C-dLop to be used as the sole input function for compartmental quantitation of P-gp function.
The primary purpose of this study was to evaluate the ability of 11 C-dLop to quantify P-gp function at the bloodbrain barrier in monkeys. A secondary purpose of this study was to examine the distribution of radioactivity in the entire body at baseline and after P-gp blockade. Because P-gp is located in many organs, its blockade might alter the distribution and metabolism of 11 C-dLop and, thereby, indirectly affect uptake into the brain.
MATERIALS AND METHODS

Radiotracer Preparation
11 C-dLop was prepared by methylation of the primary amide precursor with 11 C-iodomethane (10). The radiotracer was prepared according to our Investigational New Drug Application 78260, submitted to the U.S. Food and Drug Administration (a copy of which is available at http://pdsp.med.unc.edu/snidd/). 11 C-dLop was obtained in high radiochemical purity (.99%) and with high specific activity at the time of injection (153.8 6 111.1 GBq/mmol). The injected activity and specific activity of 11 C-dLop corresponded to a mass dose of 1.39 6 0.76 mg (range, 0.33-2.38 mg).
PET Data Acquisition
Six male rhesus monkeys (11.9 6 2.7 kg) underwent 12 PET scans of the brain; 5 scans were performed at baseline conditions and 7 were performed after P-gp blockade. Animals were immobilized with ketamine (10 mg/kg, intramuscularly), followed by anesthesia with 1.5% isoflurane in oxygen via an endotracheal tube. 11 C-dLop (320 6 56 MBq in 10 mL) was injected intravenously, and PET scans were acquired for 90 or 120 min using a highresolution research tomograph (Siemens Medical Solutions). Each scan consisted of 27 or 33 frames of increasing duration, from 30 s to 5 min. P-gp was blocked by ((2R)-anti-5-f3-[4-(10,11-dichloromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-hydroxypropoxygquinoline trihydrochloride (DCPQ) (8 or 16 mg/kg, intravenously), administered 30 min before 11 C-dLop. Eli Lilly provided DCPQ, which is a potent inhibitor of P-gp. DCPQ was previously reported as compound 14b (9). Images were reconstructed using a list-mode ordered-subset expectation maximization algorithm. Scatter and attenuation correction were applied. All data were decay-corrected to the time of radiotracer injection.
Arterial Blood Sampling
In 5 of 6 monkeys, arterial blood was sampled from an indwelling catheter in the femoral artery. We obtained 18 blood samples in heparin-treated syringes during the 2-h scan. Plasma 11 C-dLop was quantified using radio-high-performance liquid chromatography (methanol:water:triethylamine [75:25:0.1, by volume] at 2.0 mL/min) and g-counting. The plasma concentration of 11 C-dLop separated from radiolabeled metabolites was used as the input function for the compartmental analysis. The total concentration of radioactivity in whole blood was used for vascular correction of the PET data, assuming that blood constitutes 5% brain volume. Free fraction of 11 C-dLop in plasma was measured by ultrafiltration, as previously described (11) .
Compartmental Analysis
MR images of each monkey were coregistered to the summed PET image of the entire scan. Eight brain regions were identified on the PET image with reference to the coregistered MR images. The regions and their volumes (cm 3 ) were frontal cortex (1.05 6 0.14), anterior cingulate (0.31 6 0.11), temporal cortex (0.72 6 0.10), parietal cortex (1.16 6 0.06), hippocampus (0.43 6 0.11), occipital cortex (1.70 6 0.19), putamen (0.78 6 0.07), and cerebellum (1.10 6 0.17). The concentration of radioactivity in each region was expressed as standardized uptake value (SUV): %SUV 5 (% injected activity per cm 3 brain) · (g body weight). One-and 2-tissue-compartment models were applied to calculate the rate constants (K 1 , k 2 , k 3 , and k 4 ) and total distribution volume (V T ) (12) . Nonlinear parameter fitting was performed using PMOD 2.9 (PMOD Technologies). The identifiability of the rate constants were obtained from the diagonal of the covariance matrix and expressed as a percentage of the variable itself.
Cerebral Blood Flow (CBF) Measurement
To measure CBF, 4 of the 6 monkeys received 15 O-water ( 15 O-H 2 O) scans. For each monkey, 2 injections of 15 O-H 2 O (148 MBq each) were administered, and each injection was followed by a 1-min acquisition. The water scans began at 30 min before each 11 C-dLop injection and were separated by 15 min to allow activity to decay. For the P-gp-blocked condition, the 2 water scans began at 15 min after the DCPQ injection. That is, DCPQ was given at 45 min before 11 C-dLop. In 2 of the 4 monkeys, we also measured radioactivity in continual arterial blood samples after injecting 15 O-H 2 O. Regions of interest defined on the coregistered MR image for the 11 C-dLop image were applied directly to the water image, assuming no movement between the 15 O-H 2 O and 11 CdLop scans. Absolute blood flow was calculated using an autoradiographic method (13) . With absolute blood flow (F) and K 1 , we further calculated the extraction fraction (E) using the following equation:
Eq. 1 where
and PS is the permeability-surface-area product.
Whole-Body Dosimetry Study
Four male rhesus monkeys (12.1 6 2.6 kg) underwent 7 wholebody PET scans at baseline and after P-gp blockade with DCPQ (8 mg/kg, intravenously). After an intravenous injection of 11 CdLop (333 6 60 MBq), 2-dimensional scans were acquired on the Advance tomograph (GE Healthcare) in 4 segments of the body (head to upper thigh) in frames of increasing duration (75 s to 15 min) for a total scan time of 120 min (22 frames). Tomographic images were compressed from front to back into a single planar image. Regions of interest were drawn over source organs that could be visually identified-namely, the brain, lungs, liver, kidneys, and thyroid. Residence times from the monkeys were converted into corresponding human values by a scaling factor based on organ and body weights of the 2 species, as described previously (14) . Radiation absorption doses were calculated for a 70-kg adult male using OLINDA/EXM 1.0 (15).
RESULTS
P-gp Inhibition-Increased Brain Uptake
Under baseline conditions, the concentration of radioactivity in the brain was low (;50% SUV) and had low washout (Figs. 1A and 2A). To avoid overfitting the noise associated with low concentrations of radioactivity, we used only the 1-tissue model for compartmental analysis. The resulting values for V T and K 1 were small in all brain regions, averaging 3.6 6 0.6 mLÁcm 23 and 0.035 6 0.010 mLÁcm 23 Ámin 21 , respectively (average of 8 brain regions from 3 scans in 3 monkeys).
After P-gp inhibition by DCPQ (8 mg/kg), radioactivity in the brain rapidly increased to a peak of 250% SUV (Figs. 1A and 2B). However, the washout was still slow, and radioactivity decreased only to 200% SUV at 120 min. The unconstrained 2-tissue-compartment model provided a better fit than did the 1-tissue-compartment model but with only marginal statistical significance ( Fig. 1A ; F test, P , 0.05). Furthermore, the 2-tissue-compartment model estimated the kinetic parameters, particularly k 3 and k 4 , with poor identifiability (e.g., .50%). In contrast, the 1-tissuecompartment model estimated V T , K 1 , and k 2 with better identifiability (1%25%). Therefore, we chose the 1-tissuecompartment model for subsequent analyses.
P-gp blockade increased V T of 11 C-dLop by about 5-fold using the 1-tissue-compartment model. This increase was primarily due to an increase in K 1 , because k 2 was similar at baseline and after P-gp blockade (Table 1 ). V T of 11 C-dLop remained relatively stable over the 120 min of image acquisition (Fig. 3) . For example, V T calculated from 50 min of imaging was within 10% of that calculated from the entire 120 min.
Because radioactivity in the brain increased quickly and remained relatively stable after P-gp blockade, we evaluated the area under the time-activity curve as a simplified measure of brain uptake that does not require plasma measurements. This simplified analysis essentially assumes that brain uptake is irreversible and quantifies the accumulated uptake. Area under the time-activity curve from 0 to 30 min was linearly and strongly correlated with K 1 after P-gp blockade for the 8 brain regions in all 4 monkeys ( Fig.  4A ; all, r . 0.95).
The increased brain uptake of radioactivity caused by DCPQ was not a secondary, peripheral effect of increased concentration of 11 C-dLop in plasma. In fact, the peak concentration and clearance of 11 C-dLop from plasma were similar at baseline and after P-gp blockade (Fig. 1B) . Furthermore, DCPQ had insignificant effects on the plasma-free fractions of 11 C-dLop, which were 15.4% 6 1.8% at baseline and 15.8% 6 1.4% after DCPQ in 3 monkeys (P 5 0.85).
Effect of CBF P-gp inhibition increased radioactivity to variable degrees in brain regions but always with the same rank order. For example, P-gp inhibition always increased radioactivity the most in the putamen and cerebellum and least in the frontal cortex and hippocampus. We considered 2 possibilities for this differential uptake of 11 C-dLop. One possibility was that P-gp function is not uniformly distributed in the brain. A second possibility was that uptake is dependent on regional blood flow, which has reproducible patterns in anesthetized animals. For this second possibility, regions with higher blood flow would have greater uptake of radioactivity. In fact, 11 C-dLop uptake, measured using the area under the time-activity curve from 0 to 30 min, correlated linearly with relative blood flow in the 8 brain regions in all 4 monkeys. (Fig. 4B ; r 5 0.94, P , 0.001). The correlation was also observed visually by the similar distribution of radioactivity in the 11 C-dLop and 15 O-H 2 O images (Figs. 2B and 2D ).
We corrected brain uptake of 11 C-dLop for blood flow after P-gp blockade using a relative method, which compared flow in each region to that in the cerebellum. The scatter plot of blood flow versus 11 C-dLop uptake in the 8 regions was fitted to a straight line for each monkey (Fig.  5A ). A linear correction was then applied to the timeactivity curves (Fig. 5B ) for 11 C-dLop in each region on the basis of blood flow relative to that in the cerebellum. As expected, this correction moved the regional curves together so they were almost overlapping for the initial 25-50 min (Fig. 5C) . However, the curves began to diverge after about 50 min, suggesting that factors other than blood flow affect the latter portion of the time-activity curve. Nevertheless, these results show that, after correction for relative blood flow, the uptake of 11 C-dLop was fairly uniform among these large brain regions, and therefore suggest that the function of P-gp is also fairly uniform in the brain.
Absolute Blood Flow and Extraction Fraction
Because the uptake of 11 C-dLop was dependent in part on blood flow, we measured absolute blood flow, which is required to calculate extraction fraction and permeabilitysurface-area product. Among these parameters, the primary effect of P-gp is on permeability (P). That is, P-gp decreases the permeability of drugs that are substrates for this efflux transporter. This primary effect to decrease permeability causes the values of E and K 1 to decrease (Eqs. 1 and 2).
In 3 of the 4 monkeys, absolute blood flow was calculated after injection of 15 O-H 2 O by measuring radioactivity in arterial blood and the brain. Regional blood flow (mLÁcm 23 Ámin 21 ) was similar at baseline (0.32-0.64) and after P-gp blockade (0.37-0.95; Table 2 ). Parietal cortex and putamen had the lowest and highest flow, respectively, under both conditions.
We estimated the single-pass extraction fraction (E) of 11 C-dLop by performing simulations using Equations 1 and 2. The simulated relationship between K 1 and F, based on a calculated mean extraction rate (from the 8 regions), fit the observed values for both baseline and P-gp blockade conditions (Fig. 6) . The averaged extraction fraction of all 8 regions was 0.09 under the baseline condition but increased to between 0.31 and 0.58 after P-gp blockade (Table 2) .
DCPQ could theoretically increase brain uptake by blocking P-gp or by increasing blood flow. To assess the latter possibility, we measured CBF at baseline and after P-gp blockade. Relative blood flow measured as %SUV did not show significant changes after DCPQ administration. In addition, absolute blood flow increased only 24% after DCPQ (P , 0.01; Table 2 ). In contrast, extraction increased about 5-fold. Thus, the primary effect of DCPQ to increase brain uptake of 11 C-dLop was inhibition of P-gp (as measured by increase in extraction) and not the relatively small increase in absolute blood flow.
Whole-Body Biodistribution
The brain, lungs, liver, and kidneys were visually identified as organs with moderate to high activities (Fig. 7) . The liver had the highest uptake of 11 C-dLop, with an average peak of 39% injected activity at about 15 min after injection. The lungs and kidneys also exhibited relatively high uptake of radioactivity, with respective peak values of 31% and 11% injected activity at 2 min. Uptake in the brain slowly increased during the scan before leveling off at 2% injected activity at about 80 min. P-gp blockade had significant effects only in the brain, which increased from 2% at baseline to 3% injected activity after P-gp blockade.
Human residence times were estimated using average values from the planar images (Supplemental Table 1 ; supplemental materials are available online only at http:// jnm.snmjournals.org). The organs with highest radiation exposure (mSv/MBq) were the thyroid (67), kidney (34), and liver (32) (Supplemental Table 2 ). P-gp blockade had significant effects only in the brain, for which radiation exposure increased from 3 to 5 mSv/MBq. The estimated effective dose (mSv/MBq) for humans was 9.4 and 8.9 at baseline and after P-gp blockade, respectively.
DISCUSSION
The purpose of this study was to evaluate the ability of 11 C-dLop to quantify P-gp function at the blood-brain barrier using compartmental modeling. P-gp blockade increased brain uptake of radioactivity about 5-fold, compared with low uptake at baseline (;50% SUV). As predicted from the mechanism of P-gp action, the increased 
and putamen (d), the 2 brain regions with lowest and highest uptake, respectively. Each curve was average from 4 monkeys after P-gp blockade (DCPQ, 8 mg/kg, intravenously). Error bars represent identifiability, expressed as percentage of variable itself. For each region, V T was calculated with scan durations varying from 20 to 120 min, with 10-min increments. Value of V T was normalized to that determined using entire 120 min. uptake was primarily caused by an approximately 5-fold increase of entry into the brain (K 1 ), with minimal effect on exit from the brain (k 2 ). Our results are consistent with the finding that P-gp acts at the vascular endothelium (16) and prevents the entry of substrates into the brain. After P-gp blockade, brain uptake was rapid and dependent on blood flow. The effect of CBF was corrected with both relative and absolute measurements. With such corrections, brain uptake of 11 C-dLop in 8 relatively large regions was similar, which suggests that P-gp function is fairly uniformly distributed in the brain.
Whole-body imaging showed that the radiation exposure of 11 C-dLop is modest (;9 mSv/MBq), which is consistent with the short half-life of 11 C (20.4 min). Finally, P-gp blockade with DCPQ had relatively little effect on the distribution of radioactivity in the body, with the exception of the brain. This result confirmed that the effect of P-gp blockade to increase brain uptake was at the blood-brain barrier and not in the periphery.
Prolonged Retention of 11 C-dLop in Brain
After P-gp blockade with DCPQ, brain uptake of 11 CdLop was rapid and relatively stable, despite rapidly declining concentrations of the radiotracer in plasma. We do not know the reasons for the prolonged retention of radioactivity in the brain, but it is unlikely to be due to either radiometabolites or receptor binding. Radiometabolites probably do not accumulate in monkey brains, because rodent studies showed that the vast majority (90%) of radioactivity extracted from the brain at 30 min was parent radiotracer (10) . In addition, we previously reported that the brain uptake of 11 C-dLop could not be displaced by the opiate receptor antagonist naloxone or by loperamide itself (10) . Thus, the prolonged uptake is not caused by reversible receptor binding. We do not know the reasons for the retention, but ionic trapping is a possibility. That is, intracellular 11 C-dLop may be protonated and trapped by a positive charge within a vesicle, as occurs with many drugs with a dissociation constant in the range of 7-8 (17). In fact, the apparent dissociation constant of dLop is 7.3 (10), which would allow ionic trapping in the acidic medium of vesicles such as lysosomes.
Extraction Fraction and Blood Flow
We calculated 11 C-dLop to have a single-pass extraction in the brain of about 40% ( Table 2 ), meaning that about 40% of total 11 C-dLop in plasma entered the brain during each passage through the capillary bed. This extraction fraction is relatively large and is even larger than the plasma-free fraction of 11 C-dLop (;16%). Therefore, 11 CdLop must dissociate from plasma proteins during the brief (122 s) passage through brain capillaries.
The extraction of 11 C-dLop after complete P-gp blockade is probably greater than 40%. We previously showed that DCPQ increased brain uptake of 11 C-dLop almost linearly in the dose range of 4-16 mg/kg (10), with no evidence of a maximal effect. Thus, complete P-gp blockade would increase brain uptake even further, implying that the extraction after complete blockade of P-gp would be greater than 40%.
The high brain extraction of 11 C-dLop and resulting dependence on blood flow have important implications for the capacity of P-gp and the measurement of its function. First, the high extraction (.40%) confirms both the rapidity and the high capacity of P-gp function at the blood-brain barrier. Our results in monkeys are consistent with prior studies in rats that showed the high capacity of P-gp at the blood-brain barrier, compared with the testes and lymphocytes (18) . Second, because of the high extraction of 11 CdLop, regional brain data should be corrected for blood flow to measure the function of P-gp.
Whole-Body Dosimetry
In our whole-body biodistribution study of 11 C-dLop, we found the highest uptake of radioactivity in the liver, lungs, and kidneys. Despite the high uptake in the kidneys, little radioactivity was excreted via the urine (Fig. 7) . Instead, the majority of radioactivity was likely excreted from the liver to the gastrointestinal tract. Should 11 C-dLop be demethylated (10), the resulting 1 carbon molecule could be exhaled as 11 C-carbon dioxide. We assessed this possibility by measuring the total radioactivity over the entire field of view (i.e., from head to mid thigh) over the 120 min of scanning. This measured radioactivity did not decline over time, suggesting that little radioactivity was exhaled during the course of the scan.
The distribution of radioactivity in organs of the body other than the brain is difficult to interpret relative to the known distribution of P-gp (19) . For example, because P-gp FIGURE 6 . Correlation between absolute CBF and rate of brain entry (K 1 ) after injection of 11 C-dLop at baseline in 1 animal (n) and after P-gp blockade in 2 animals (d and :). Symbols represent 8 brain regions from each monkey. Curves show theoretic relationship between CBF and K 1 using Equations 1 and 2. Theoretic values of K 1 were generated using mean permeability and surface product (PS) calculated from CBF and K 1 of 8 regions for each study.
FIGURE 7.
Maximum-intensity-projection images after injection of 11 C-dLop at baseline (top) and after P-gp blockade (bottom) conditions at 1, 5, and 90 min after radiotracer injection.
is known to excrete many drugs via the urine, we predicted the baseline scan would show significant accumulation of radioactivity in the urinary bladder and that P-gp blockade would decrease this route of excretion. In fact, under both baseline and blocked conditions, the kidney had high amounts of radioactivity, and the urinary bladder could not even be identified. The brain was the only organ that showed an easily interpreted effect. That is, P-gp blockade increased brain uptake from low levels at baseline to modest levels after P-gp blockade. The corresponding residence times increased from 0.013 h at baseline to 0.021 h after P-gp blockade. This modest 50% increase in radioactivity underestimated that from the kinetic brain studies, because the planar analysis used the compressed whole-body images. That is, the uptake at baseline (0.013 h) was artificially high, because the sampled region included muscle and skull anterior and posterior to the brain. In fact, the planar analysis may also explain why we saw no noticeable effect in peripheral organs, like the testes, known to express P-gp (i.e., tomographic imaging might have shown that P-gp blockade allowed entry of 11 C-dLop into some peripheral organs, such as the testes).
CONCLUSION
We found that 11 C-dLop is a promising radiotracer to measure P-gp function at the blood-brain barrier. Brain uptake is low at baseline, consistent with the rapid action and high capacity of P-gp. Pharmacologic blockade of P-gp causes about a 5-fold increase of peak brain activity, which is largely explained by about a 5-fold increase of brain entry (K 1 ). The single-pass extraction of 11 C-dLop is high (.40%) and requires correction for regional blood flow to determine the specific effects of P-gp to block entry of substrates into the brain.
